This has taken years of scientific research and a culmination of years of data which we protect via IP-protected technologies – adapted and applied to the cannabis segment – and the Company maintains exclusive and royalty-free licenses to the various complementary technologies that serve as our building blocks.
Our Strains for Pains App cross references our proprietary data and patent pending technology to provide medical recommendations using specific cannabis strains or brands to the clients specific illness or ailment.
Using Strains For Pains Mobile or Desktop App, Doctors now have access to decision making tools to give personalized cannabis treatments.
Our Extensive Database of strains, cannabinoids, and medicinal applications helps Dispensaries give great recommendations.
We cross reference to the clients specific illness or ailment
This calculated recommendation is followed up by referring the client to the nearest dispensary or clinic. We will have a dedicated mobile app and a desktop app. Our technology is proprietary. We have accumulated a huge database of strains, cannabinoids, and medicinal applications. Our management and advisory team is involved in pain management, computers, neuroscience and technology.
There are hundreds of cannabis strains, each offering a combination of medical use and effect. At Strains For Pains we offer a solution. We are a medical marijuana data recommendation system. Our facility uses algorithms as tools to guide patients to the right amount of levels of of cannabinoid , strains and brands of medical cannabis , and specific methods of use and consumption. We cross reference to the clients specific illness or ailment.
StrainsforPains provides valuable information for new and experienced medical marijuana patients, lessens their reliance on experimentation and guesswork, and improves their confidence in consistent and personalized cannabis treatments.
BOARD OF ADVISORS
Dr. Bindiya Moorjani was a awarded a Ph.D. in biomedical sciences from the Fishberg Research Center for Neurobiology, Mount Sinai School of Medicine, New York University. Dr. Moorjani has authored several scientific studies that have been published in scientific journals. She did major studies on Serotonin. From 1993 through 1999, Dr. Moorjani was a graduate researcher at the Mount Sinai School of Medicine in the doctoral program concentrating on neurobiology.
Dr. Michael Stern, MDDr. Michael Stern graduated from medical school in 1973 and since 1983 has been a board-certified urologist and urologic surgeon. Dr. Stern served as an adjunct clinical faculty member at Bastyr University School of Naturopathic Medicine for 11 years (1995 –2006). Dr. Stern operates the Northwest Healthy Options Clinic in Seattle, Washington. Dr. Stern continues advising patients on lifestyle issues and alternative healthy treatments for a wide variety of diseases, including medical cannabis.
Yeshua Shainberg, 63, Founder and CEO. He is the originator of the business strategy. He has directed the company on issues of engineering and compliance matters. His background includes successful financings for various companies dating back to 1987. In 1987 he implemented and helped create the Koala Blue concept with Olivia Newton-John. This required a master franchise computerized system. In 1994 he visualized and co-created the first Umbilical cord stem cell concepts and technologies. This required an intensive computer program for selection of candidates cross referenced to patient. In 1995 he was the key investment banker for the IPO of Diehl Graphsoft (DIEG) a CAD/CAM competitor to Autocad. In 1999 DIEG was bought out. It remains one of the leading companies for Cad Cam and computerized architectural drawing products on the market. Mr. Shainberg advised and consulted with several other companies on capital raise financings, computer programs, as well as mergers and acquisitions.
As a key driver of our future growth and value creation strategy, the Company will be expanding its business in Q1 2020 with innovative new features like strain search, dispensary menu integration, a discount program, user profiles, affiliate product marketing, and an advertising sales program that serves as the bridge between medical marijuana patients and other businesses in the industry. There is a severe shortage of medical data in this emerging field and we have developed technology that will enable us to aggregate, curate, analyze, and package accurate data that benefits all cannabis stakeholders.
Our product and technology strategy uses pre-existing, fully-vetted and IP-protected technologies – adapted and applied to the cannabis segment – and the Company maintains exclusive and royalty-free licenses to the various complementary technologies that serve as our building blocks.
We seek to fill that need by creating the industry standard for cannabis-related advice, selection, terminology, and data, all without touching the actual plant – enabling the Company to work in any regulatory environment. Our product and technology strategy uses pre-existing, fully-vetted and IP-protected technologies – adapted and applied to the cannabis segment – and the Company maintains exclusive and royalty-free licenses to the various complementary technologies that serve as our building blocks.
DOCTORS, DISPENSARIES AND PATIENTS
We now have access to decision making tools on the go via our Smartphone App which lessens their reliance on experimentation and guesswork, and improves their confidence in consistent and personalized cannabis treatments.